...
search icon
fulc-img

Fulcrum Therapeutics Inc Share Price

FULC
NMQ
$10.715
-$0.14
(-1.29%)
1D
Industry: Pharmaceuticals Sector: Health Care

Fulcrum Therapeutics Inc Analyst Forecast

Fulcrum Therapeutics Inc Share Price Chart

Fulcrum Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$716.44M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
188.38K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.18
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.31 L
$15.74 H
$10.715

About Fulcrum Therapeutics Inc, Common Stock

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Fulcrum Therapeutics Inc Stock Returns

Time FrameFULCSectorS&P500
1-Week Return13.72%0.75%0.54%
1-Month Return14.2%-0.88%-2.01%
3-Month Return29.9%2.08%-0.28%
6-Month Return66.06%18.91%6.04%
1-Year Return205.06%6.98%12.92%
3-Year Return-13.6%16.78%65.15%
5-Year Return-21.93%33.02%73.52%
10-Year Return-19.56%142.35%266.07%

Fulcrum Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue8.82M19.16M6.34M2.81M80.00M[{"date":"2020-12-31","value":11.03,"profit":true},{"date":"2021-12-31","value":23.95,"profit":true},{"date":"2022-12-31","value":7.93,"profit":true},{"date":"2023-12-31","value":3.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue2.38M2.52M76.78M71.80M63.39M[{"date":"2020-12-31","value":3.1,"profit":true},{"date":"2021-12-31","value":3.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.51,"profit":true},{"date":"2024-12-31","value":82.55,"profit":true}]
Gross Profit8.82M19.16M(70.44M)2.81M16.61M[{"date":"2020-12-31","value":46.04,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-367.58,"profit":false},{"date":"2023-12-31","value":14.64,"profit":true},{"date":"2024-12-31","value":86.7,"profit":true}]
Gross Margin100.00%100.00%(1110.69%)100.00%20.77%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1110.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":20.77,"profit":true}]
Operating Expenses80.43M100.22M42.12M113.47M38.51M[{"date":"2020-12-31","value":70.89,"profit":true},{"date":"2021-12-31","value":88.32,"profit":true},{"date":"2022-12-31","value":37.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":33.94,"profit":true}]
Operating Income(71.61M)(81.05M)(112.56M)(110.66M)(21.90M)[{"date":"2020-12-31","value":-7161100000,"profit":false},{"date":"2021-12-31","value":-8105400000,"profit":false},{"date":"2022-12-31","value":-11256100000,"profit":false},{"date":"2023-12-31","value":-11066400000,"profit":false},{"date":"2024-12-31","value":-2189700000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(70.82M)(80.85M)(109.87M)(97.33M)(9.72M)[{"date":"2020-12-31","value":-7081900000,"profit":false},{"date":"2021-12-31","value":-8084700000,"profit":false},{"date":"2022-12-31","value":-10987100000,"profit":false},{"date":"2023-12-31","value":-9733500000,"profit":false},{"date":"2024-12-31","value":-972500000,"profit":false}]
Income Taxes(2.38M)(2.52M)(4.25M)2.00M-[{"date":"2020-12-31","value":-118.71,"profit":false},{"date":"2021-12-31","value":-125.49,"profit":false},{"date":"2022-12-31","value":-212.06,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(70.82M)(80.85M)(109.87M)(98.71M)(9.72M)[{"date":"2020-12-31","value":-7081900000,"profit":false},{"date":"2021-12-31","value":-8084700000,"profit":false},{"date":"2022-12-31","value":-10987100000,"profit":false},{"date":"2023-12-31","value":-9871400000,"profit":false},{"date":"2024-12-31","value":-972500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(68.44M)(78.33M)(109.87M)(97.33M)(9.72M)[{"date":"2020-12-31","value":-6844000000,"profit":false},{"date":"2021-12-31","value":-7833200000,"profit":false},{"date":"2022-12-31","value":-10987100000,"profit":false},{"date":"2023-12-31","value":-9733500000,"profit":false},{"date":"2024-12-31","value":-972500000,"profit":false}]
EPS (Diluted)(2.81)(2.29)(2.48)(1.58)(0.33)[{"date":"2020-12-31","value":-281,"profit":false},{"date":"2021-12-31","value":-229,"profit":false},{"date":"2022-12-31","value":-248,"profit":false},{"date":"2023-12-31","value":-158,"profit":false},{"date":"2024-12-31","value":-33.33,"profit":false}]

Fulcrum Therapeutics Inc Ratios

Fulcrum Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

FULC
Cash Ratio 17.25
Current Ratio 17.70

Fulcrum Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

FULC
ROA (LTM) -20.63%
ROE (LTM) -31.21%

Fulcrum Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

FULC
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Fulcrum Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

FULC
Trailing PE NM
Forward PE NM
P/S (TTM) 5.12
P/B 3.44
Price/FCF NM
EV/R 117.40
EV/Ebitda NM

FAQs

What is Fulcrum Therapeutics Inc share price today?

Fulcrum Therapeutics Inc (FULC) share price today is $10.715

Can Indians buy Fulcrum Therapeutics Inc shares?

Yes, Indians can buy shares of Fulcrum Therapeutics Inc (FULC) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FULC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Fulcrum Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Fulcrum Therapeutics Inc (FULC) via the Vested app. You can start investing in Fulcrum Therapeutics Inc (FULC) with a minimum investment of $1.

How to invest in Fulcrum Therapeutics Inc shares from India?

You can invest in shares of Fulcrum Therapeutics Inc (FULC) via Vested in three simple steps:

  • Click on Sign Up or Invest in FULC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Fulcrum Therapeutics Inc shares
What is Fulcrum Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Fulcrum Therapeutics Inc (FULC) is $15.74. The 52-week low price of Fulcrum Therapeutics Inc (FULC) is $2.31.

What is Fulcrum Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Fulcrum Therapeutics Inc (FULC) is

What is Fulcrum Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Fulcrum Therapeutics Inc (FULC) is 3.44

What is Fulcrum Therapeutics Inc dividend yield?

The dividend yield of Fulcrum Therapeutics Inc (FULC) is 0.00%

What is the Market Cap of Fulcrum Therapeutics Inc?

The market capitalization of Fulcrum Therapeutics Inc (FULC) is $716.44M

What is Fulcrum Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Fulcrum Therapeutics Inc is FULC

How Can Investors Use Fulcrum Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Fulcrum Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Fulcrum Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Fulcrum Therapeutics Inc shares for Indian investors?

When investing in Fulcrum Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Fulcrum Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Fulcrum Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Fulcrum Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Fulcrum Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top